Patrick M. Moriarty

3.1k total citations · 2 hit papers
40 papers, 1.7k citations indexed

About

Patrick M. Moriarty is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Patrick M. Moriarty has authored 40 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 9 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Economics and Econometrics. Recurrent topics in Patrick M. Moriarty's work include Lipoproteins and Cardiovascular Health (25 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Patrick M. Moriarty is often cited by papers focused on Lipoproteins and Cardiovascular Health (25 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Patrick M. Moriarty collaborates with scholars based in United States, Canada and United Kingdom. Patrick M. Moriarty's co-authors include Sotirios Tsimikas, Erik S.G. Stroes, Jean Bergeron, Marie T. Baccara‐Dinet, Marlys L. Koschinsky, Daniel J. Rader, John R. Guyton, Paul D. Thompson, Yunling Du and Robert Pordy and has published in prestigious journals such as Journal of the American College of Cardiology, The Journal of Clinical Endocrinology & Metabolism and European Heart Journal.

In The Last Decade

Patrick M. Moriarty

38 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

2015 345 citations Patrick M. Moriarty, Paul D. Thompson et al. Journal of clinical lipidology profile →
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

2018 329 citations Sotirios Tsimikas, Sergio Fazio et al. Journal of the American College of Cardiology profile →

Peers

Patrick M. Moriarty

SURGE

CCM

EDM

Christopher E. Kurtz United States

Claudia Stefanutti Italy

Roeland Huijgen Netherlands

Garen Manvelian United States

Lulu Ren Sterling United States

Norman E. Lepor United States

Laurens F. Reeskamp Netherlands

Ovidio Muñiz-Grijalvo Spain

Mary P. McGowan United States

Christopher E. Kurtz United States

Patrick M. Moriarty

1.3k ×1.0

SURGE

617 ×1.6

CCM

360 ×1.0

EDM

483 ×1.5

207 ×0.7

Citations per year, relative to Patrick M. Moriarty Patrick M. Moriarty (= 1×) peers Christopher E. Kurtz

Countries citing papers authored by Patrick M. Moriarty

Since Specialization

Citations

This map shows the geographic impact of Patrick M. Moriarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Moriarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Moriarty more than expected).

Fields of papers citing papers by Patrick M. Moriarty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Moriarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Moriarty. The network helps show where Patrick M. Moriarty may publish in the future.

Co-authorship network of co-authors of Patrick M. Moriarty

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Moriarty. A scholar is included among the top collaborators of Patrick M. Moriarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Moriarty. Patrick M. Moriarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmid, Sabine, Sierra Cheng, Miguel García-Pardo, et al.. (2022). Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 24(1). 40–50. 14 indexed citations

Schmid, Sabine, Miguel García-Pardo, Sierra Cheng, et al.. (2022). Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. Lung Cancer. 166. 58–62. 7 indexed citations

Tsimikas, Sotirios, Patrick M. Moriarty, & Erik S.G. Stroes. (2021). Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). Journal of the American College of Cardiology. 77(12). 1576–1589. 100 indexed citations

Willeit, Peter, Calvin Yeang, Patrick M. Moriarty, et al.. (2020). Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. Journal of the American Heart Association. 9(23). e016318–e016318. 38 indexed citations

Moriarty, Patrick M., et al.. (2020). Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Current Atherosclerosis Reports. 22(9). 48–48. 49 indexed citations

Moriarty, Patrick M., et al.. (2019). Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. Journal of clinical lipidology. 13(6). 894–900. 49 indexed citations

Boffa, Michael B., Saverio Stranges, Neil Klar, et al.. (2018). Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. Journal of clinical lipidology. 12(6). 1358–1366. 31 indexed citations

Tsimikas, Sotirios, Sergio Fazio, Keith C. Ferdinand, et al.. (2018). NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology. 71(2). 177–192. 329 indexed citations breakdown →

Backes, James M., Brittany L. Melton, Janelle F. Ruisinger, Crystal Burkhardt, & Patrick M. Moriarty. (2018). Comparing patients’ prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid. Journal of clinical lipidology. 13(1). 170–175.

10.

Moriarty, Patrick M., et al.. (2017). Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke. Journal of Clinical Apheresis. 32(6). 574–578. 9 indexed citations

11.

Awad, Kamal, Dimitri P. Mikhailidis, Peter P. Tóth, et al.. (2017). 81Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. European Heart Journal. 38(suppl_1).

12.

Sandesara, Pratik B., et al.. (2016). Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease. Journal of clinical lipidology. 11(1). 282–286. 10 indexed citations

13.

Devonshire, Virginia, Anthony Feinstein, & Patrick M. Moriarty. (2016). Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Research Notes. 9(1). 148–148. 13 indexed citations

14.

Moriarty, Patrick M. & Linda Hemphill. (2016). Lipoprotein Apheresis. Endocrinology and Metabolism Clinics of North America. 45(1). 39–54. 29 indexed citations

15.

Moriarty, Patrick M., Klaus G. Parhofer, Stephan P. Babirak, et al.. (2016). Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. Journal of clinical lipidology. 10(3). 627–634. 15 indexed citations

16.

Moriarty, Patrick M. & Linda Hemphill. (2015). Lipoprotein Apheresis. Cardiology Clinics. 33(2). 197–208. 22 indexed citations

17.

Grand’Maison, François, Virender Bhan, Mark S. Freedman, et al.. (2013). Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS Care. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 40(4). 527–535. 6 indexed citations

18.

Moriarty, Patrick M.. (2006). LDL-apheresis therapy. Current Treatment Options in Cardiovascular Medicine. 8(4). 282–288. 23 indexed citations

19.

Xiao, Ming, Asud Khaliq, Patrick M. Moriarty, et al.. (1996). The effect of scatter laser photocoagulation on intravitreal levels of growth factors in the miniature pig. Current Eye Research. 15(9). 923–931. 5 indexed citations

20.

Khaliq, Asud, et al.. (1995). Oxygen modulates production of bFGF and TGF-β by retinal cells in vitro. Experimental Eye Research. 60(4). 415–423. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact